Drug Firms Face Cost Squeeze As Beijing Starts Centralized EDL Bidding Process
This article was originally published in PharmAsia News
Multinational and domestic drug firms in China brace for mounting price pressure as Beijing starts its centralized bidding process for essential drugs.
You may also be interested in...
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.
Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.